Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RGS12 | O14924 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | DCK | P27707 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402263 | 0.87 | SMN1; SMN2 (0.54) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL844787 | 0.83 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2LMNAPKM | |
| SCHEMBL844198 | 0.83 | MEN1 (0.53) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6637914 | 0.80 | MEN1 (0.57) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13067205 | 0.80 | NPSR1 (0.41) | MEN1KMT2ARAB9ASMN1; SMN2LMNA | |
| SCHEMBL862001 | 0.77 | L3MBTL1 (0.40) | MEN1KMT2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL6638190 | 0.76 | MAPT (0.58) | MEN1KMT2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL6639107 | 0.75 | RAB9A (0.51) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21338203 | 0.75 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL13066757 | 0.75 | RAB9A (0.39) | MEN1KMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| EP-2432776-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | Chlorion Pharma, Inc. (CA) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | MEN1 4378/4885KMT2A 3590/4885RAB9A 3092/4885 |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | MEN1 4378/4885KMT2A 3590/4885RAB9A 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.